These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 21984119)

  • 41. Structural changes in the German pharmaceutical market: price setting mechanisms based on the early benefit evaluation.
    Henschke C; Sundmacher L; Busse R
    Health Policy; 2013 Mar; 109(3):263-9. PubMed ID: 23339876
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Accident Risk in the Production Sector of EU Countries-Cohort Studies.
    Nowacki K
    Int J Environ Res Public Health; 2021 Mar; 18(7):. PubMed ID: 33807270
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [The European Union and drugs].
    Viala G; Campion MD
    Ann Pharm Fr; 1995; 53(4):184-7. PubMed ID: 7574273
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The single market for pharmaceuticals in the European Union in light of European Court of Justice rulings.
    Kanavos P
    Pharmacoeconomics; 2000 Dec; 18(6):523-32. PubMed ID: 11227392
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Constrained competition in parallel drug importation: the case of simvastatin in Germany, the Netherlands, and the United Kingdom].
    Costa-Font J; Kanavos P
    Gac Sanit; 2007; 21(1):53-9. PubMed ID: 17306187
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Reference pricing of pharmaceuticals for Medicare: evidence from Germany, The Netherlands, and New Zealand.
    Danzon PM; Ketcham JD
    Front Health Policy Res; 2004; 7():1-54. PubMed ID: 15612334
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Economics and structure of the generic pharmaceutical industry.
    Kirking DM; Ascione FJ; Gaither CA; Welage LS
    J Am Pharm Assoc (Wash); 2001; 41(4):578-84. PubMed ID: 11486984
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmaceutical policies in European countries.
    Barros PP
    Adv Health Econ Health Serv Res; 2010; 22():3-27. PubMed ID: 20575226
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Drug price regulation under consumer moral hazard. Two-part tariffs, uniform price or third-degree price discrimination?
    Felder S
    Eur J Health Econ; 2004 Dec; 5(4):324-9. PubMed ID: 15759171
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Association Between Market Competition and Prices of Generic Topical Dermatology Drugs.
    Li DG; Joyce C; Mostaghimi A
    JAMA Dermatol; 2018 Dec; 154(12):1441-1446. PubMed ID: 30383117
    [TBL] [Abstract][Full Text] [Related]  

  • 51. European healthcare policies for controlling drug expenditure.
    Ess SM; Schneeweiss S; Szucs TD
    Pharmacoeconomics; 2003; 21(2):89-103. PubMed ID: 12515571
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A comparison of generic drug prices in seven European countries: a methodological analysis.
    Wouters OJ; Kanavos PG
    BMC Health Serv Res; 2017 Mar; 17(1):242. PubMed ID: 28359273
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A Comparative Study of the Market Configuration of the Japanese Pharmaceutical Market Using the Gini Coefficient and Herfindahl-Hirschman Index.
    Shibata S; Fukumoto D; Suzuki T; Ozaki K
    Ther Innov Regul Sci; 2020 Sep; 54(5):1047-1055. PubMed ID: 31989539
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparing pharmaceutical pricing and reimbursement policies in Croatia to the European Union Member States.
    Vogler S; Habl C; Bogut M; Voncina L
    Croat Med J; 2011 Apr; 52(2):183-97. PubMed ID: 21495202
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Patent indicators: a window to pharmaceutical market success.
    Guo Y; Hu Y; Zheng M; Wang Y
    Expert Opin Ther Pat; 2013 Jul; 23(7):765-71. PubMed ID: 23611022
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Impact of cross-reference pricing on pharmaceutical prices: manufacturers' pricing strategies and price regulation.
    Stargardt T; Schreyögg J
    Appl Health Econ Health Policy; 2006; 5(4):235-47. PubMed ID: 17249840
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Parallel import of drug preparations. A study of price development of parallel import preparations versus original preparations].
    Schou HS
    Ugeskr Laeger; 1993 Jun; 155(26):2024-8. PubMed ID: 8328041
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Analysis of the Italian generic medicines retail market: recommendations to enhance long-term sustainability.
    Dylst P; Vulto A; Simoens S
    Expert Rev Pharmacoecon Outcomes Res; 2015 Feb; 15(1):33-42. PubMed ID: 25138241
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of generic drug competition on the price of prescription drugs in Ontario.
    Lexchin J
    CMAJ; 1993 Jan; 148(1):35-8. PubMed ID: 8439888
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Decreasing utilization and increasing prices of brand-name oral contraceptive pills: Implications to societal costs and market competition.
    Zhang JX
    PLoS One; 2020; 15(6):e0234463. PubMed ID: 32525965
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.